IP Library › Granted Patent US 7,494,804
Granted Patent B2
US 7,494,804 · App. 10/351,157 · Granted Feb 24, 2009

Polynucleotide encoding cytokine receptor zcytor17 multimer

Assignee: ZymoGenetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,494,804
App. No.
10/351,157
Granted
Feb 24, 2009
Kind
B2
Abstract

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

Claims (40)

1. An expression vector comprising the following operably linked elements:

a) a first transcription promoter; a first DNA segment encoding a first cytokine receptor polypeptide comprising amino acid residues 20–732 of SEQ ID NO:111; and a first transcription terminator, and

b) a second transcription promoter; a second DNA segment encoding a second cytokine receptor polypeptide comprising amino acid residues 28–979 of SEQ ID NO:7; and a second transcription terminator;

wherein the first cytokine receptor polypeptide and the second cytokine receptor polypeptide form a multimeric or heterodimeric cytokine receptor; and

wherein the multimeric or heterodimeric cytokine receptor binds to a ligand comprising amino acid residues 27–164 of SEQ ID NO:2.

2. A cultured cell comprising the expression vector of claim 1 , wherein the cell expresses the first cytokine receptor polypeptide and the second cytokine receptor polypeptide encoded by the DNA segments.

3. A method of producing a multimeric or heterodimeric cytokine receptor comprising:

culturing a cell according to claim 2 ; and

isolating the multimeric or heterodimeric cytokine receptor produced by the cell.

4. A cultured cell comprising:

a first expression vector comprising:

a) a first transcription promoter;

b) a first DNA segment encoding a first cytokine receptor polypeptide comprising amino acid residues 20–732 of SEQ ID NO:111; and

c) a first transcription terminator; and

a second expression vector comprising:

a) a second transcription promoter;

b) a second DNA segment encoding a second cytokine receptor polypeptide comprising amino acid residues 28–979 of SEQ ID NO:7; and

c) a second transcription terminator;

wherein the first cytokine receptor polypeptide and the second cytokine receptor polypeptide form a multimeric or heterodimeric cytokine receptor; and

wherein the multimeric or heterodimeric cytokine receptor binds to a ligand comprising amino acid residues 27–164 of SEQ ID NO:2.

5. A method of producing an antibody to a soluble multimeric or heterodimeric cytokine receptor comprising a first cytokine receptor polypeptide consisting of amino acid residue 20 to amino acid residue 519 of SEQ ID NO:111 and a second cytokine receptor polypeptide consisting of amino acid residues 28–739 of SEQ ID NO:7, the method comprising:

inoculating an animal with the soluble multimeric or heterodimeric cytokine receptor, wherein the soluble multimeric or heterodimeric cytokine receptor elicits an immune response in the animal to produce an antibody that specifically binds the soluble multimeric or heterodimeric cytokine receptor; and

isolating the antibody from the animal.

6. A method of producing a multimeric or heterodimeric cytokine receptor comprising:

culturing a cell according to claim 4 ; and

isolating the multimeric or heterodimeric cytokine receptor produced by the cell.

7. A cultured cell comprising an expression vector comprising the following operably linked elements;

a transcriptional promoter;

a DNA segment encoding a soluble cytokine receptor polypeptide comprising amino acid residues 20-519 of SEQ ID NO: 111: and

a transcriptional terminator and a second expression vector comprising:

a second transcription promoter;

a second DNA segment encoding a second soluble cytokine receptor polypeptide comprising amino acid residues 28–739 of SEQ ID NO:7; and

a second transcription terminator;

wherein the cell expresses the soluble cytokine receptor polypeptide encoded by the DNA segment and the second soluble cytokine receptor polypeptide encoded by the second DNA segment to form a soluble multimeric or heterodimeric cytokine receptor.

8. A method of producing a soluble multimeric or heterodimeric cytokine receptor comprising:

culturing a cell according to claim 7 ; and

isolating the soluble multimeric or heterodimeric cytokine receptor produced by the cell.

9. A composition comprising:

a soluble multimeric or heterodimeric cytokine receptor comprising a first soluble cytokine receptor polypeptide comprising amino acid residues 20–519 of SEQ ID NO:111 and a second soluble cytokine receptor comprising amino acid residues 28–739 of SEQ ID NO:7; and

a pharmaceutically acceptable vehicle.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2008
From: SPRECHER, CINDY A.; GAO, ZEREN; KUIJPER, JOSEPH L.; DASOVICH, MARIA M.; GRANT, FRANCIS J.; PRESNELL, SCOTT R.; WHITMORE, THEODORE E.; HAMMOND, ANGELA K.; NOVAK, JULIA E.; GROSS, JANE A.; DILLON, STACEY R.
To: ZYMOGENETICS, INC.
Reel/Frame 021069/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2003
From: SPRECHER, CINDY A.; GAO, ZEREN; KUIJPER, JOSEPH L.; DASOVICH, MARIA M.; GRANT, FRANCIS J.; PRESNELL, SCOTT R.; WHITMORE, THEODORE E.; HAMMOND, ANGELA K.; NOVAK, JULIA E.; GROSS, JANE A.; DILLON, STACEY R.
To: ZYMOGENETICS, INC.
Reel/Frame 014595/0421 →
Continuity (4)
Provisional Application 6043536100 · Dec 19, 2002
Provisional Application 6038910800 · Jun 14, 2002
Provisional Application 6035032500 · Jan 18, 2002
Related Publication 20030215838A1 · Nov 20, 2003